| Literature DB >> 33043314 |
Devin Skoll1, Jennifer C Miller1, Leslie A Saxon1.
Abstract
In December 2019, the novel COVID-19 virus spread from a cluster of pneumonia cases in Wuhan, China, to every corner of the globe, creating a worldwide pandemic pushing hospital systems past capacity and bringing economies worldwide to a halt. The COVID-19 pandemic is unique in comparison to prior coronavirus epidemics in its superior ability to be spread by asymptomatic and presymptomatic patients, allowing the virus to silently evade traditional symptoms-based screening approaches. Countries have implemented cutting-edge digital solutions to enhance traditional contact-tracing methodologies in combination with novel testing strategies to combat the virus, with variable levels of success. Despite having one of the most advanced and expensive health care systems in the world, the United States (U.S.) response is arguably one of the world's largest failures, as it leads the globe in case number as well as deaths. Until a successful vaccine can be broadly distributed, it is imperative that the U.S. curb the viral spread by rapidly developing a framework implementing both enhanced tracing and testing strategies balancing the needs of public health while respecting individual liberties. This review will explore the role of technology-augmented contact-based surveillance in tracking the outbreak in select countries in comparison to the current U.S. approach. It will evaluate barriers in the U.S. to implementing similar technologies, focusing on privacy concerns and a lack of unified testing and tracing strategy. Finally, it will explore strategies for rapidly scaling testing in a cost-effective manner.Entities:
Keywords: COVID-19; COVID-19 testing; Contact tracing; Digital health; Infection prevention; Infection surveillance; Public health
Year: 2020 PMID: 33043314 PMCID: PMC7531333 DOI: 10.1016/j.cvdhj.2020.09.004
Source DB: PubMed Journal: Cardiovasc Digit Health J ISSN: 2666-6936
Figure 1Digital contact-tracing strategies. a: Mandatory Centralized Mass Surveillance: South Korea, Israel, and China have employed mandatory centralized mass surveillance techniques to contact trace. If an individual is infected, officials use location data to map where he visited and evaluate who he may have exposed before being diagnosed. Location data can be obtained by CCTV footage, facial recognition cameras, location-tracking bracelets, and cell phone tower signals. QR codes can also be used to track one’s location, as people must scan them on their smartphones to enter public areas. Citizens obtain a code by entering personal details and possible history of COVID-19 symptoms or exposure. They are assigned different color codes (green, yellow, red) based on their likelihood of infection. Green code holders are allowed to travel, yellow code holders cannot travel, and red code holders must quarantine.b: Voluntary Contact-Tracing Applications: Apps can be divided into 2 categories based on whether data are collected in a centralized or decentralized manner. When 2 people come into contact, their phones exchange anonymized key codes. When B becomes infected, he updates his status in the app. In a centralized approach, B uploads both his ID code and all the codes of people he has been in contact with to a central server. The central server, usually run by a public health authority, uses the codes to do contact matching and sends alerts to those exposed to B. In a decentralized approach, B only uploads his ID to the central server and keeps his contact history on his phone. All other phones regularly download codes from the cloud that are uploaded from positive cases. Each phone then compares the downloaded codes with its contact history and if there is a match, the phone alerts the user of exposure. Countries like France, Singapore, New Zealand, and Australia have centralized apps. Germany, Ireland, the U.K., Italy, Canada, Austria, Switzerland, Latvia, and Denmark have decentralized apps.
Figure 2Pooled testing: Sample pooling allows multiple people to be tested at once. Swab samples are collected from each individual. Half of each sample is combined in a pool with the others, and half is set aside in case a retest is needed to confirm positivity. If the pool is negative, then all samples in that pool are cleared as negative. If the pool is positive, it means that 1 or more of the individuals in that pool are positive, so each sample is tested again individually.
COVID-19 testing strategies
| Test | Target | Use | Speed | Sensitivity | Specificity | PPV | NPV | Manufacturer(s) |
|---|---|---|---|---|---|---|---|---|
| RT-PCR | Viral RNA | Active virus | 2–12 hours | Gold standard (100%) | Gold standard (100%) | 100% | 100% | Roche, Abbott, and LabCorp |
| Isothermal nucleic acid amplification test | Viral RNA | Active virus | 5–15 minutes | >94.7% | >98.6% | >78.1% | >99.7% | Abbott |
| Viral antigen test | Antigen | Active virus | 15 minutes | 80% | 100% | 100% | 99% | Quidel |
| Lateral flow assay | Antigen | Active virus | 15 minutes | 97.1% | 98.5% | 77.3% | 99.8% | Abbott |
| Lateral flow assay | Total binding antibodies | Immunity | <1 hour | 93.8-100% | 96%–98.8% | 55.2%–80.8% | 99.7%–100% | Cellex and Assure |
| Chemiluminescence immunoassay | Total binding antibodies | Immunity | 30 minutes | 97.6%–100% | 99% | 84%–88% | 100% | Abbott and DiaSorin |
| Enzyme-linked immunoabsorbent assay | Total binding antibodies | Immunity | <1 hour | 92.5% | 99%–100% | 100% | 99.6% | Mount Sinai and InBios |
| Surrogate virus neutralization test | Neutralizing antibodies | Immunity | 1 hour | 95%–100% | 100% | 100% | 99.9% | GenScript Biotech |
NPV = negative predictive value; PPV = positive predictive value; RT-PCR = reverse transcription polymerase chain reaction.
Not an exhaustive list.
Assuming 5% prevalence.